Dipeptide species regulate p38MAPK-Smad3 signalling to maintain chronic myelogenous leukaemia stem cells

Nature Communications

Volumn 6, Issue , 2015, Pages

  Naka, Kazuhito ^a,b   Jomen, Yoshie ^a   Ishihara, Kaori ^a   Kim, Junil ^c   Ishimoto, Takahiro ^a   Bae, Eun Jin ^a,c   Mohney, Robert P ^d   Stirdivant, Steven M ^d   Oshima, Hiroko ^a   Oshima, Masanobu ^a   Kim, Dong Wook ^e   Nakauchi, Hiromitsu ^f,g   Takihara, Yoshihiro ^b   Kato, Yukio ^a   Ooshima, Akira ^c   Kim, Seong Jin ^c  

^a KANAZAWA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c CHA University   (South Korea)

^d METABOLON INC   (United States)

^e The Catholic University of Korea   (South Korea)

^f UNIVERSITY OF TOKYO   (Japan)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; DIPEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; SMAD3 PROTEIN; TRANSCRIPTION FACTOR FKHRL1; COMPLEMENTARY DNA; COTRANSPORTER; HYDROGEN-COUPLED OLIGOPEPTIDE TRANSPORTER PEPT2; SMAD3 PROTEIN, MOUSE;

AMINO ACID; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; INHIBITION; METABOLISM; PEPTIDE; RODENT; SURVIVAL; VIABILITY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVITY; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL; IN VIVO STUDY; INTERNALIZATION; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; CANCER STEM CELL; CLASSIFICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; RETROVIRIDAE; TRANSGENIC MOUSE;

MURINAE;

ANIMALS; DIPEPTIDES; DNA, COMPLEMENTARY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MICE; MICE, TRANSGENIC; NEOPLASTIC STEM CELLS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RETROVIRIDAE; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; SYMPORTERS;

EID: 84939825908     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms9039     Document Type: Article

References (55)

1. O'Hare, T., Zabriskie, M. S., Eiring, A. M. & Deininger, M. W. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat. Rev. Cancer 12, 513-526 (2012).
2. Bhatia, R. et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 101, 4701-4707 (2003).
3. Druker, B. J. et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355, 2408-2417 (2006).
4. Mahon, F. X. et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 11, 1029-1035 (2010).
5. Ross, D. M. et al. Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR. Leukemia 24, 1719-1724 (2010).
6. Sinclair, A., Latif, A. L. & Holyoake, T. L. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br. J. Pharmacol. 169, 1693-1707 (2013).
7. Zhang, H. & Li, S. Molecular mechanisms for survival regulation of chronic myeloid leukemia stem cells. Protein Cell 4, 186-196 (2013).
8. Reynaud, D. et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell 20, 661-673 (2011).
9. Li, L. et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 21, 266-281 (2012).
10. Zhang, B. et al. Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 21, 577-592 (2012).
11. Daniel, H. & Kottra, G. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology. Pflugers Arch. 447, 610-618 (2004).
12. Smith, D. E., Clemencon, B. & Hediger, M. A. Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol. Aspects Med. 34, 323-336 (2013).
13. Sugiura, T., Umeda, S., Tsuji, A. & Kato, Y. in Pharmacogenomics of Human Drug Transporters: Clinical Impacts. (eds Ishikawa, T., Kim, R.B. & König, J.) 223-242 (2013).
14. Krause, D. S. et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. Nat. Med. 19, 1513-1517 (2013).
15. Naka, K. et al. TGF-b-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 463, 676-680 (2010).
16. Massagué, J., Seoane, J. & Wotton, D. Smad transcription factors. Genes Dev. 19, 2783-2810 (2005).
17. Huettner, C. S., Zhang, P., Van Etten, R. A. & Tenen, D. G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24, 57-60 (2000).
18. Koschmieder, S. et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood 105, 324-334 (2005).
19. Simsek, T. et al. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 7, 380-390 (2010).
20. Takubo, K. et al. Regulation of glycolysis by Pdk functions as a metabolic checkpoint for cell cycle quiescence in hematopoietic stem cells. Cell Stem Cell 12, 49-61 (2013).
21. Kato, Y., Yoshida, K., Watanabe, C., Sai, Y. & Tsuji, A. Screening of the interaction between xenobiotic transporters and PDZ proteins. Pharm. Res. 21, 1886-1894 (2004).
22. Ishimoto, T. et al. Organic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons. PLoS ONE 9, e89434 (2014).
23. Luckner, P. & Brandsch, M. Interaction of 31 b-lactam antibiotics with the H+/peptide symporter PEPT2: analysis of affinity constants and comparison with PEPT1. Eur. J. Pharm. Biopharm. 59, 17-24 (2005).
24. Zoncu, R., Efeyan, A. & Sabatini, D. M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 12, 21-35 (2011).
25. Jewell, J. L., Russell, R. C. & Guan, K. L. Amino acid signalling upstream of mTOR. Nat. Rev. Mol. Cell Biol. 14, 133-139 (2013).
26. Foster, K. G. et al. Regulation of mTOR complex 1 (mTORC1) by raptor Ser863 and multisite phosphorylation. J. Biol. Chem. 285, 80-94 (2010).
27. Gwinn, D. M. et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 30, 214-226 (2008).
28. Shaw, R. J. et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646 (2005).
29. Ito, K. et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 453, 1072-1078 (2008).
30. Møller, G. M., Frost, V., Melo, J. V. & Chantry, A. Upregulation of the TGFb signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia. FEBS Lett. 581, 1329-1334 (2007).
31. Duy, C. et al. BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature 473, 384-388 (2011).
32. Pellicano, F. et al. The anti-proliferative activity of kinase inhibitors in chronic myeloid leukaemia cells is mediated by FOXO transcription factors. Stem Cells 32, 2324-2337 (2014).
33. Seoane, J., Le, H. V., Shen, L., Anderson, S. A. & Massagué, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211-223 (2004).
34. Mullen, A. C. et al. Master transcription factors determine cell-type-specific responses to TGF-b signaling. Cell 147, 565-576 (2011).
35. Wang, G., Matsuura, I., He, D. & Liu, F. Transforming growth factor-binducible phosphorylation of Smad3. J. Biol. Chem. 284, 9663-9673 (2009).
36. Blom, N., Sicheritz-Ponten, T., Gupta, R., Gammeltoft, S. & Brunak, S. Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics 4, 1633-1649 (2004).
37. Kamaraju, A. K. & Roberts, A. B. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor-b-mediated Smad-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 280, 1024-1036 (2005).
38. Alarcón, C. et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-b pathways. Cell 139, 757-769 (2009).
39. Casas-Terradellas, E., Tato, I., Bartrons, R., Ventura, F. & Rosa, J. L. ERK and p38 pathways regulate amino acid signalling. Biochim. Biophys. Acta 1783, 2241-2254 (2008).
40. Yamazaki, S. et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 147, 1146-1158 (2011).
41. Takeishi, S. et al. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 23, 347-361 (2013).
42. Miyamoto, K. et al. Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 1, 101-112 (2007).
43. Campbell, R. M. et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol. Cancer Ther. 13, 364-374 (2014).
44. Goldstein, D. M., Kuglstatter, A., Lou, Y. & Soth, M. J. Selective p38a inhibitors clinically evaluated for the treatment of chronic inflammatory disorders. J. Med. Chem. 53, 2345-2353 (2010).
45. Schreiber, S. et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4, 325-334 (2006).
46. Bonfils, G. et al. Leucyl-tRNA synthetase controls TORC1 via the EGO complex. Mol. Cell 46, 105-110 (2012).
47. Han, J. M. et al. Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell 149, 410-424 (2012).
48. Thomas, J. D. et al. Rab1A is an mTORC1 activator and a colorectal oncogene. Cancer Cell 26, 754-769 (2014).
49. Wang, S. et al. Metabolism. Lysosomal amino acid transporter SLC38A9 signals arginine sufficiency to mTORC1. Science 347, 188-194 (2015).
50. Rebsamen, M. et al. SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature 519, 477-481 (2015).
51. Jewell, J. L. et al. Metabolism. Differential regulation of mTORC1 by leucine and glutamine. Science 347, 194-198 (2015).
52. Ho, K. K. et al. Phosphorylation of FOXO3a on Ser-7 by p38 promotes its nuclear localization in response to doxorubicin. J. Biol. Chem. 287, 1545-1555 (2012).
53. Bae, E. et al. Definition of Smad3 phosphorylation events that affect malignant and metastatic behaviors in breast cancer cells. Cancer Res. 74, 6139-6149 (2014).
54. Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207-210 (2002).
55. Benito, R. et al. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression. Pharmacogenet. Genomics 22, 381-388 (2012).